Michelle Xia, co-founder and CEO of Akeso Biopharma, has been selected for the TIME100 Health 2025 list for her contributions to the development of the global life science field as well as for the outstanding achievements of the company in innovative development of biopharmaceuticals.

Michelle Xia, an expert in molecular biology and antibody drug development, founded Akeso Biopharma in 2012 and has since led the company in establishing a world-class, end-to-end drug development system, creating a series of first-in-class and best-in-class innovative drugs.

At present, Akeso Biopharma has grown into a biopharmaceutical company engaged in the development, clinical testing, manufacturing and commercialization of innovative biological drugs with global innovation competitiveness and influence.